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AbstrACt
Introduction Surgery is the primary curative treatment 
for oesophageal cancer, with considerable recent 
improvements in long- term survival. However, surgery has 
a long- lasting impact on patient’s health- related quality of 
life (HRQOL). Through a multicentre European study, our 
research group was able to identify key symptoms that 
affect patient’s HRQOL. These symptoms were combined 
to produce a tool to identify poor HRQOL following 
oesophagectomy (LAsting Symptoms after Oesophageal 
Resection (LASOR) tool). The objective of this multicentre 
study is to validate a six- symptom clinical tool to identify 
patients with poor HRQOL for use in everyday clinical 
practice.
Methods and analysis Included patients will: (1) be aged 
18 years or older, (2) have undergone an oesophagectomy 
for cancer between 2015 and 2019, and (3) be at least 
12 months after the completion of adjuvant oncological 
treatments. Patients will be given the previously created 
LASOR questionnaire. Each symptom from the LASOR 
questionnaire will be graded according to impact on 
quality of life and frequency of the symptom, with a 
composite score from 0 to 5. The previously developed 
LASOR symptom tool will be validated against HRQOL as 
measured by the European Organisation for Research and 
Treatment of Cancer QLQC30 and OG25.
sample size With a predicted prevalence of poor HRQOL 
of 45%, based on the previously generated LASOR clinical 
symptom tool, to validate this tool with a sensitivity and 
specificity of 80%, respectively, a minimum of 640 patients 
will need to be recruited to the study.
Ethics and dissemination NHS Health Research 
Authority (North East—York Research Ethics Committee) 
approval was gained 8 November 2019 (REC reference 
19/NE/0352). Multiple platforms will be used for the 
dissemination of the research data, including international 
clinical and patient group presentations and publication of 
research outputs in a high impact clinical journal.
IntroduCtIon
Globally, oesophageal cancer is the 12th 
most common cancer type and the 7th most 
common cause of cancer- related death, 
with an overall 5- year survival of less than 
20%.1–3 The mainstay of curative treatment 
for oesophageal cancer is surgical resection, 
which is often combined with chemotherapy 
or chemoradiotherapy.4 5 This multimodality 
approach to treatment, along with central-
isation of oesophageal cancer surgery to 
high- volume centres and the introduction 
of minimally invasive approaches to surgery, 
has been associated with major recent 
improvements in short- term and oncological 
outcomes and survival.6–8
With the recent improvements in survival, 
the assessment of patient- reported outcome 
measures including patient’s health- 
related quality of life (HRQOL) and the 
impact of long- term symptoms in survivor-
ship has become increasingly important. 
However, current data regarding the long- 
term symptom burden following poten-
tially curative oesophagectomy are limited 
strengths and limitations of this study
 ► Large, multicentre, contemporenous, European 
study of quality of life after esophagectomy.
 ► Comparison will be performed with more compre-
hensive quality of life tools (European Organisation 
for Research and Treatment of Cancer- QLQC30 and 
OG25).
 ► Quality of Life Questionnaire/LAsting Symptoms af-
ter Oesophageal Resection (LASOR) tool has been 
developed in association with patient with oesoph-
ageal cancer support group charities (Heartburn 
Cancer UK and Oesophageal Patients Association).
 ► The LASOR tool will be validated in patients who 
have had potentially curative oesophageal surgery 
within 1–4 years and could suffer some bias of well- 
motivated patients responding to invites and some 
patients suffering from symptoms of undiagnosed 
recurrent cancer being included.
 ► Patients who have already suffered recurrent cancer 
or early postoperative death will not be included.
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and evidence- based interventions are lacking. One 
population- based cohort study suggested approximately 
40% of patients seek medical attention for long- term 
symptoms, associated with increased depression and 
anxiety.9
The European Organisation for Research and Treat-
ment of Cancer (EORTC) have developed question-
naires for the assessment of HRQOL during treatment 
for oesophageal cancer.10 11 These tools have been widely 
used in a research setting to assess the impact on HRQOL 
of multimodality treatment, variations in surgical tech-
nique and complications.12 13 However, the EORTC- 
QLQC30 and OG25 modules are often considered too 
cumbersome to be routinely used in clinical practice. 
Furthermore, despite frequently being used in cancer- 
free survivorship, these questionnaires are not designed 
for this purpose, when the nature of symptoms and their 
HRQOL impact may be significantly different, compared 
with the context of diagnosis and treatment.
Through a multicentre European study of 876 patients, 
we recently identified three key symptoms that were inde-
pendently associated with poor HRQOL as measured by 
validated EORTC tools.14 We presented these findings to 
the Oesophageal Patient Association (UK) and Heart-
burn Cancer UK patient support groups who identified 
a further three symptoms to be included in the final clin-
ical symptom tool that we aim to validate in this present 
UK study.
objECtIvEs
Global objective
 ► To validate a six- symptom clinical tool to identify 
patients with poor HRQOL more than 1 year after 
surgery, for use in everyday clinical practice.
specific objectives
1. Validate a six symptom clinical tool to identify patients 
with poor HRQOL as measured by current EORTC 
QLQC30 and OG25 tools.
2. To assess patient acceptability of this clinical symptom- 
based tool for postoperative clinical follow- up.
MEthods And AnAlysIs
study design
Cross- sectional study to validate a symptom question-
naire in the identification of patients with poor HRQOL 
following oesophageal cancer surgery. Eligible patients 
from the UK will be invited to complete the LAsting 
Symptoms after Oesophageal Resection (LASOR) tool 
(table 1) and the EORTC QLQC30 and OG25 question-
naires. Centres from the existing Association of Upper 
Gastro- intestinal Surgeons for Great Britain and Ireland 
(AUGIS) research network will be contacted for inclu-
sion in the study, and patients will be consented locally to 
participate in the study (online supplementary appendix 
A). The study will begin in October 2020 and run till 
October 2021 for patient recruitment, with analysis 
completed and ready for presentation and publication in 
December 2021. Patients will be sent the questionnaire 
electronically or in paper form based on their preference 
indicated at the time of consent to complete the ques-
tionnaire at home and avoid reporting bias. Patients who 
fail to respond or complete the questionnaire will receive 
one telephone or electronic reminder and if they fail to 
respond will be excluded from the study.
Measures
Archival data
This data will be collected retrospectively from the patient 
medical records (online supplementary appendix B).
Demographic information
Data on pretreatment; patient age, sex, body mass index, 
ethnic background, socioeconomic status (Carstairs 
index), education level, smoking status and medical 
comorbidities (collated with Charlson Comorbidity 
Index) will be collected through review of medical 
records.
Table 1 LAsting Symptoms after Oesophageal Resection symptom tool
Symptom
Q1. Do you have any of the following symptoms 
and how often? Please mark
Q2. What is the impact of these 
symptoms to your quality of life?
Never Rarely Weekly Daily
Multiple 
times per 
day None Some Substantial
Low mood               
Reduced energy or activity tolerance               
Pain on scars from chest               
Heartburn/acid/bile (sour/bitter 
tasting)
              
Diarrhoea (>3 times per day) 
unrelated to eating
              
Bloating or cramping after eating               
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Tumour and treatment information
Information on stage, tumour location, type of surgery, 
postoperative complications as defined by the Esopha-
geal Complications Consensus Group,15 and neoadjuvant 
and adjuvant therapy used will be collected by reviewing 
medical records.
Complications after 12 months
Specific data on long- term complications including anas-
tomotic stricture requiring dilatation and hiatal hernia 
will be collected by reviewing medical records.
Outcome data
Each symptom from the LASOR questionnaire will 
be graded according to impact on quality of life and 
frequency of the symptom, with a composite score from 
0 to 5. Each EORTC HROQL symptom item comprised 
four categories on a Likert scale: (1) not at all; (2) a little; 
(3) quite a bit; (4) very much. The previously developed 
LASOR symptom tool will be validated against HRQOL 
as measured by the EORTC QLQC30 and OG25. Patients 
will also be asked to complete a questionnaire (online 
supplementary appendix C) describing their satisfaction 
in completing the LASOR tool.
Inclusion criteria
 ► Patients aged over 18 years at the time of surgery.
 ► Patients treated with oesophagectomy for oesopha-
geal or gastro- oesophageal junctional cancer (Siewert 
I and II) between January 2015 and June 2019.
 ► Patients at least 12 months post completion of cancer 
treatment (surgical or oncological).
Exclusion criteria
 ► Any patient who lacks capacity or is unable to provide 
informed consent.
 ► Any patient below 18 years of age at the time of 
surgery.
 ► Any patient with evidence of cancer recurrence as 
detected by local centres based on their own routine 
follow- up protocol.
sample size
Using simple nomograms, with a predicted prevalence of 
poor HRQOL of 45%,14 based on the previously gener-
ated LASOR clinical symptom tool, to validate this tool 
with a sensitivity and specificity of 80%, respectively, a 
minimum of 640 patients would need to be recruited 
to the study. We anticipate an expected response rate of 
80% and thus 800 patients would need to be recruited to 
the study.
statistical methodology
Each symptom from the LASOR questionnaire will graded 
according to impact on quality of life and frequency of the 
symptom, with a composite score from 0 to 5 (table 2). 
Each EORTC HROQL symptom item comprises four 
categories on a Likert scale: (1) not at all; (2) a little; 
(3) quite a bit; (4) very much. Linear transformation of 
Likert scores for answers in each conceptual area will be 
performed as per EORTC recommendations. Symptom 
scores hence comprise a numeric value from 0 to 100, 
with higher scores indicating more pervasive symptoms. 
Poor HRQOL will be defined as having poor function 
and poor symptom in QLQ- C30 and QlQ- OG25 (by 
answering ‘Quite a Bit’/‘Very Much’ problems to at least 
one question each in function and symptom scales).16 17 
Patients who do not answer ‘Quite a Bit’/‘Very Much’ will 
be considered as having good HRQOL. The area under 
the receiver operating characteristics curve will be used 
as a measure of overall accuracy of the prediction model 
from the LASOR tool in the identification of patients 
with poor HRQOL as measured by EORTC QLQ- C30 and 
QlQ- OG25 tools.
PAtIEnt And PublIC InvolvEMEnt
how was the development of the research question 
and outcome measures informed by patients’ priorities, 
experience and preferences?
We presented the findings of our development study to 
the Oesophageal Patient Association (UK) and Heart-
burn Cancer UK patient support groups who identified 
a further three symptoms to be included in the final clin-
ical symptom tool that we aim to validate in this present 
UK study.
how did you involve patients in the design of this study?
P Behrens was a former patient and the patient repre-
sentative who directly supported and contributed to the 
development of this protocol. His review was critical in 
the design of this protocol.
Were patients involved in the recruitment to and conduct of 
the study?
P Behrens and patient representatives from the Oesoph-
ageal Patient Association (UK) and Heartburn Cancer 
Table 2 Symptom based grading system including 
prevalence and impact on quality of life (QOL)—each 
symptom from the LAsting Symptoms after Oesophageal 
Resection questionnaire will graded according to impact on 
QOL and frequency of the symptom, with a composite score 
from 0 to 5
Symptom level QOL impact and frequency
0 No symptom present
1 QOL impact=none
2 QOL impact=some and frequency=rarely/
weekly
3 QOL impact=some and frequency=daily/
multiple
4 QOL impact=substantial and 
frequency=rarely/weekly
5 QOL impact=substantial and 
frequency=daily/multiple
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UK patient support group will be part of the steering 
committee for this study.
how will the results be disseminated to study participants?
Study findings will be disseminated at Oesophageal 
Patient Association (UK) and Heartburn Cancer UK 
patient support group meetings.
dIssEMInAtIon
Multiple methods of dissemination will be employed 
to ensure the findings from this research will reach 
relevant stakeholders including patients, primary care 
practitioners, scientists, hospital specialists in gastroen-
terology, oncology and surgery, health policy- makers and 
commissioners as well as healthcare regulatory bodies. 
The study findings will be presented at international 
gastroenterology, oncology and surgical research meet-
ings. The findings of this research will also be presented 
to relevant patient groups. Ultimately, we plan to publish 
the results of this research in a high impact factor clin-
ical journal to allow widespread dissemination of this 
research. Further as this trial will be run through the 
AUGIS research network, the external validity of this tool 
will be high within the UK population, and thus we antic-
ipate the translation to clinical practice would be faster. 
Patient acceptability will also be tested and if acceptable, 
will further facilitate clinical implementation.
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